

**Instand**  
**NGS**  
for Personalized Therapy

**Precision Diagnostics for  
Precision Cancer Care**

Improving patient access to innovation

**High Level Seminar**

European Parliament – Brussels  
May 20<sup>th</sup>, 2025 - 14:00-18:00 CET

Join us for a high-level panel discussion  
on the role of precision diagnostics in  
improving cancer care across Europe.

For further details and registration  
[www.instandngs4p.eu](http://www.instandngs4p.eu)  
For inquiries, contact  
[events@instandngs4p.eu](mailto:events@instandngs4p.eu)



Cofunded by the European Union  
under Grant Agreement No. 874719

# PPRELIMINARY PROGRAMME

14.00	<p><b>Welcome</b> - <b>Prof. Kurt Zatloukal</b> - Project Coordinator - Director - Diagnostic and Research Institute of Pathology - Medical University of Graz - Austria</p> <p><b>Alexandru Padurean</b> - Project Officer - HaDEA - EU Commission</p>
14.10	<p><b>Addresses of MEPs</b>      <b>Vlad Voiculescu</b> – Romania - RENEW Europe</p>

14.20	<p><b>Session 1 – Medical need of NGS and precision diagnostics in cancer care</b></p> <p><b>Moderator:</b> <b>Prof. Ruth Ladenstein</b> - Senior Consultant in Paediatric Oncology - St. Anna Children's Cancer Research Institute - Austria, Coordinator ERN PaedCan - Board Member SIOP Europe</p> <p><b>Speaker:</b> <b>Dr. Olivier Tredan</b> – Coordinator Medical Oncology Dept. - Centre Léon Bérard - France</p> <p><b>Panel Discussion</b></p> <p><b>Dr. Marc van den Bulcke PhD</b> - Head of Service – Sciensano - Belgium</p> <p><b>Prof. Paolo Casali</b> - Director Medical Oncology Unit 2 - &amp; Secretary of the Ethics Committee – Istituto -- - Project Coordinator of Joint Action On Networks of Expertise on Cancer - Board Member ESMO</p> <p><b>Prof. Francesco de Lorenzo</b> - President F.A.V.O. - Italian Federation of Volunteer Cancer Patient Organisations - Board Member of the European Academy of Cancer Sciences-EACS</p> <p><b>Prof. Klaus Pantel</b> - Director of Institute of Tumor Biology - University Hospital Eppendorf (UKE) - University of Hamburg - Germany</p> <p><b>Open Floor and Wrap Up</b></p>
-------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

15.20

## Session 2: How can innovative technologies meet regulatory requirements for in vitro diagnostics and how European standards can help

**Moderator:** **Prof. Kurt Zatloukal** - Project Coordinator - Director - Diagnostic and Research Institute of Pathology - Medical University of Graz - Austria

**Speaker:** ***Innovative Workflow Technologies and European Standards meet Regulatory Requirements***

**Dr. Uwe Oelmüller** - Vice President, Head of the Molecular Diagnostics Technology Center for Sample Technologies - QIAGEN GmbH - Germany

### Panel Discussion:

**Niklas Blomberg** - Executive Director - IHI Innovative Health Initiative

**Francesca Fenizia** - Executive Director IQNPath - Naples - Italy

**Matthijs van Meerveld** - EFPIA Oncology Platform

Representative - Associate Vice President - Global Head of Access Policy & Patient Advocacy - Oncology Dept. - Menarini - Zurich - Switzerland

**Prof. Peter Riegman (em.)** - Head Tissue Bank - Advisor Central Biobank Erasmus MC - Erasmus University - Rotterdam

**Jesus Rueda Rodriguez** - Director-General of Strategies and Special Projects MedTech - Brussels - Belgium

Open Floor and Wrap Up

## Coffee Break

16.40	<p><b>Session 3: Health economic benefits of NGS as prerequisite for reimbursement schemes. How to overcome inequalities for patients in accessing precision diagnostics in Europe</b></p> <p><b>Moderator:</b> <b>Prof. Wim van Harten</b> - Research Group Leader - The Netherlands Cancer Institute, Amsterdam - Chair Working Group Health Economics, OEI - (em) Professor Quality Management and Health Care Technology</p> <p><b>Speaker:</b> <b><i>Health economics and access to precision medicine in oncology in Europe</i></b>  <b>Prof. Valesca Retèl</b> - Endowed professor - Health Technology Assessment - Erasmus School of Health Policy &amp; Management</p> <p><b>Panel Discussion:</b></p> <p><b>Dr. Marc van den Bulcke PhD</b> - Head of Service - Sciensano – Belgium</p> <p><b>Prof. Fortunato Ciardiello</b> - Director - Division of Medical Oncology - Dean of the School of Medicine and Surgery - University of Campania Luigi Vanvitelli - Naples</p> <p><b>Francesco Florindi</b> - Policy Officer - DG Research &amp; Innovation - Unit D2 Health Innovations &amp; Ecosystems - Brussels - Belgium</p> <p><b>Prof. Lotte Steuten</b> - Deputy Chief Executive - Office of Health Economics, London</p> <p>Open Floor and Wrap Up</p>
	<p><b>Conclusions</b>  <b>Prof. Marialuisa Lavitrano</b> - School of Medicine and Surgery - University Milano-Bicocca - Italy</p>
18.30 - 19.30	<p><b>Cocktail Reception (Location to be advised)</b></p>

